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icroRNAs (miRNAs) are single-
stranded RNA molecules of 
approximately 22 nucleotides. 
They regulate protein expression by binding 
to and suppressing translation of messenger 
RNAs. Less than 20 years ago, they were 
unheard of, but the number of identifi  ed 
miRNAs is growing.
This burgeoning fi  eld captured Anto-
nio Giraldez’s attention while he was a PhD 
student studying Drosophila wing morpho-
genesis (1–3), yet he didn’t start his own 
experiments on the subject until after he had 
started his postdoc. Better late than never, 
as Giraldez’s studies produced 
important data showing that ze-
brafi  sh zygotes unable to make 
their own miRNAs cannot un-
dergo brain morphogenesis, 
and that one particular miRNA 
can rescue the defect (4, 5).
Now running his own 
laboratory at Yale, Giraldez has 
stuck with zebrafi  sh and inves-
tigates how miRNAs shape 
gene expression to orchestrate 
embryonic development (6).
WINE, WINGS, AND A PHD
Whereabouts in Spain did you grow up?
Jerez, which is south of Seville, where the 
sherry comes from. Wine is really big there, 
and my dad actually worked in a winery, as 
an administrator.
When I was little, he would bring 
home Petri dishes and beakers and gad-
gets that the scientists had given him. 
That was one of my fi  rst contacts with 
science. I had this little desk that you 
could close—that was my incubator. I 
would drive my mom crazy, spreading 
the Petri dishes with everything, seeing 
which substances would grow. You can 
imagine the smell in my room.
How did you get from Petri dishes in 
your bedroom to university in Madrid?
Actually, fi  rst I went to the University of 
Cádiz in the south to study chemistry. I did 
an undergraduate project on wine, in fact. 
But then I decided that I was more fasci-
nated by the chemistry of life. So I went to 
Madrid to study molecular biology and 
biochemistry for an extra two years.
Tell me about your wine project. What 
were you analyzing?
In white wine, polyphenolic compounds 
become oxidized in a process called 
browning (because it turns the wine brown). 
The process is infl  uenced by sunlight.
In the south, white wine is produced 
in dark bottles, as it was thought to stop 
the sun’s effect. But in other markets, they 
use clear bottles for white 
wine, and dark bottles for 
the red wine—which actu-
ally doesn’t make much sense 
because red wine doesn’t get 
easily oxidized: it’s protected 
by the tannins. The compa-
nies in the south were mak-
ing a shift toward using clear 
bottles, because of market de-
mands. So I put wine in dif-
ferent colored bottles on my 
sunroof, and found that even 
if you have your wine in a dark bottle it 
will still get completely messed up if you 
leave it in the sun. It’s better to have your 
wine in cardboard.
Madrid was where I fi  rst had contact 
with really big science. I think that the Center 
for Molecular Biology in Madrid has some 
of the greatest scientists in Spain.
In my last year of university I did a 
dissertation project with Ginés Morata—
a great developmental biologist. Working 
with him was a life-changing experience.
You weren’t tempted to stay in his 
laboratory for your PhD?
Ginés introduced me to genetics, but I 
wanted a middle ground between molecu-
lar biology and genetics. I had heard about 
the European Molecular Biology Labora-
tory (EMBL), so I went there for a summer 
internship with Steve Cohen in my last 
year of university. It was a great experi-
ence. I decided to do a PhD with Steve 
after university. Actually, there was some 
competition between the groups of Steve 
and Ginés, so it was a bit awkward.
Tell me about your PhD project.
We did an overexpression screen, where you 
randomly insert an enhancer controlled by 
gal4 (a yeast transcription factor) into the ge-
nome of fl  ies, and then cross these fl  ies with 
gal4-expressing fl  ies. This generates a library 
of fl  y lines that overexpress particular genes.
I looked for fl  ies that had defects in 
their wing development. It was an excit-
ing time. For the fi  rst year of my PhD we 
screened 20,000 lines. It was wonderful be-
cause every day you discovered something.
We found around 50 novel genes that 
could affect wing patterning. One of the 
genes that I chose to work on made a fl  y 
with no wings. Instead it would duplicate 
the notum— the back of the fl  y. It was pretty 
cool. It always amazes me how we can 
modify the development of living animals 
using genetics.
How did your interest in miRNAs start?
Steve’s laboratory was also interested in 
growth control. Using the same screen, he 
had identifi  ed an insertion that caused a par-
ticular growth defect, but for several years 
no one could fi  nd the gene. It almost ruined 
the careers of several postdocs. When the 
miRNA fi  eld started emerging, Julius Bren-
necke, a student in the laboratory, thought to 
look for a miRNA, and found one—it was 
the fi  rst miRNA identifi  ed in the fl  y.
Using zebrafish, Giraldez studies how microRNAs guide the body’s development.
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There’s a lesson: believe in the results 
rather than the hypothesis.
Absolutely. It was a mutant with a pheno-
type. It was worth pursuing because it had 
to be true.
NEW YORK
Why New York? Why Alexander Schier’s 
laboratory?
I knew I wanted to experience science in the 
US. And I had made up my mind that I want-
ed to change to a vertebrate 
system. I just had to decide 
which laboratory to go to.
When I met Alex 
for the fi  rst time, I had this 
gut feeling that joining his 
laboratory would be a good 
decision. We had a great con-
nection. It struck me that he 
was a ’70s version of Steve 
Cohen—Steve with an Aus-
tin Powers dress sense.
Tell me about the project.
I started off studying morphogens—one of 
Alex’s preferred subjects— but it didn’t 
feel like I was at the tip of the iceberg 
(although we still don’t understand how 
morphogen gradients function). Research-
ers were already moving down the morph-
ogen iceberg. In a moment of refl  ection in 
the laboratory, I thought, “This is not what 
I want to do for life.” The miRNA fi  eld, 
however, was up and coming. And I thought 
there was a good chance that miRNAs 
would be important in development.
Ronald Plasterk had produced a zy-
gotic mutant that lacked Dicer, the enzyme 
that makes miRNAs, but its phenotype was 
not as dramatic as we thought it would 
be. So we made a mutant zygote that also 
lacked any Dicer contributed by the mother 
(in the egg). Despite having no miRNAs, 
these mutants could still make many cell 
types—neurons, muscle cells, cardiomyo-
cytes, pigment cells—but the cells could 
not organize into proper functional organs.
At the time, David Bartel had cloned 
some miRNAs expressed in early zebrafi  sh 
development. I contacted him and said, 
“We have to talk.” He had found this miRNA, 
called miR-430, that was abundant in the 
zygote. The dream experiment was to put 
this miRNA in our Dicer-less embryos and 
see if it could rescue them. I told David, 
“This experiment will never work, but we 
have to try.”
Did it work?
The fi   rst time I did the experiment, I 
thought that I had mistakenly taken a wild-
type clutch. That experiment was a dream 
come true for a postdoc.
We found that miR-430 targets and 
degrades up to 40% of the maternal tran-
scripts present in the zygote. 
For more than 20 years we 
have known that degrada-
tion of the maternal mRNAs 
occurs at this time in the 
zygote. But we had no idea 
what factor was responsible 
for this degradation. miR-
430 fi  ts the puzzle perfectly.
Hasn’t miR-430 also 
been linked to cancer and 
embryonic stem cells?
Yes. So, discovering its tar-
get transcripts in the adult would be extreme-
ly important. Absolutely. In the Dicer-lacking 
embryo, miR-430 restores morphogenesis of 
organs, a process that requires cell motility. If 
miR-430 can also make cancer cells go from 
immotile to motile, you’ve got metastasis.
THE MYRIAD MIRNAS
Are you looking at other miRNAs and 
their targets?
Yes. We continue to study the effects of 
miRNAs in neural development, but have 
also moved to study the muscle. The em-
bryonic muscle is a more homogeneous 
tissue, and so it should be easier for look-
ing at gene expression changes. We’re 
comparing wild-type and Dicer mutant 
cells, and also cells where individual 
miRNAs have been removed. The beauty 
is that we can easily manipulate the embryo 
and ask what happens when we do so. 
This approach has allowed us to show 
that miRNAs really function as the sculp-
tors of gene expression that carve away 
mRNA and protein to precisely control 
embryonic development.
Why did you choose Yale?
Several reasons. My wife, Valentina Greco, 
who is also a scientist, was working in New 
York with Elaine Fuchs. So, I wanted to 
stay in the US.
But also, I was struck by the amazing 
scientifi  c caliber of my colleagues and my 
chair, Richard Lifton. He’s a great scien-
tist. And he has given me everything I need 
to succeed. So now the ball is in my court.
I also got an offer from Cold Spring 
Harbor, which is an amazing place. I had 
no idea which would be the best choice. 
It’s an experiment with no control. It was 
the toughest decision I’ve ever had to 
make, but for a good reason: I was choos-
ing between great and great.
Are you enjoying Yale so far?
Yes. The fi  rst year was the toughest of my 
scientifi  c career. Also, we had a baby three 
months after my laboratory started, so that 
made it a little more interesting.
But now the laboratory is running, and 
we’re focused on the question of how miR-
NAs regulate development. We’re searching 
for their targets and trying to understand the 
physiological functions of individual miR-
NA–target interactions. This is just the tip of 
the iceberg. miRNA targets are still relatively 
hard to identify, and many novel noncoding 
RNAs are still to come. It’s going to be ex-
tremely exciting in the future. It is already.
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A ubiquitously transcribed transgene mRNA 
gets degraded by a miRNA in muscle (top). 
When the miRNA is inhibited (bottom) the 
message is restored.
“miRNAs really 
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expression that 
carve away 
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development.”